Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death

Fig. 6

Curcumin enhances therapeutic efficacy of gefitinib in vivo through Sp1/EGFR downregulation-mediated autophagy induction. a-d H157 and H1299 cells were subcutaneously injected to the flanks of BALBL/c mice respectively. The mice were treated with vehicle (control), gefitinib, or curcumin, or the two drug combination as described in Materials and Methods. Tumor volume was measured at the time indicated after the onset of treatment. (*P<0.05 and ***P<0.001). The tumor weight was measured at the end of the experiment (*P<0.05 compared with gefitinib, or curcumin treatment alone). e Representive pictures of tumor samples from the mice bearing H157 and H1299 cell tumors receiving different treatments as indicated. f Immunoblot analysis of the expressions of Sp1, HDAC1, EGFR, survivin, LC3-II, Beclin-1 and cleaved-caspase-3 in H157 and H1299 cell tumor samples from the mice in each treatment group. All experiments were repeated three times. Similar results were obtained from three independent experiments. Typical immunoblots were presented in the Figure

Back to article page